Biogen stock falls after FDA calls for federal investigation into Alzheimers drug approval – CNBC

Biogen shares fell on Friday after the head of the Food and Drug Administration called for an investigation into the recent approval of the company’s Alzheimer’s drug, Aduhelm.
Acting FDA Commission… [+2637 chars]